Fig. 2. Cumulative incidence of acute GVHD and preemptive CMV treatment disease, PFS, and OS according to UD HSC (cryopreserved versus fresh).

The cumulative incidences of A acute graft-versus-host disease (GVHD), B preemptive therapy on CMV disease, C progression-relapse-free survival, and D overall survival are shown for the groups of patients who underwent UD HSCT with either cryopreserved (solid line) or fresh grafts (dashed line).